Van beleggers
voor beleggers
desktop iconMarkt Monitor

Inloggen

  • Geen account? Registreren

Wachtwoord vergeten?

Aandeel Galapagos AEX:GLPG.NL, BE0003818359

  • 44,120 21 okt 2021 17:38
  • -0,125 (-0,28%) Dagrange 43,800 - 44,325
  • 355.941 Gem. (3M) 359,9K

Galapagos november 2020

2.982 Posts
Pagina: «« 1 ... 95 96 97 98 99 ... 150 »» | Laatste | Omlaag ↓
  1. Joseph K. 15 november 2020 10:53
    NEWS RELEASE 13-NOV-2020
    Approved JAK inhibitor baricitinib shows promise against cytokine storm in COVID-19 clinical study
    JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality

    AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE

    Research News

    SHARE PRINT E-MAIL
    A clinical study involving 601 patients in Italy and Spain suggests that the JAK inhibitor drug baricitinib may enhance survival rates of patients with severe COVID-19, primarily by blunting the runaway immune inflammation known as "cytokine storm." While the authors are careful to note that their study was not a fully randomized trial with a placebo control group, the drug nonetheless had a notable effect, particularly in the Spanish treatment cohort, composed entirely of elderly patients over the age of 70. This suggests the treatment could address high rates of COVID-19 morbidity and mortality observed in this demographic worldwide. Further in vitro experiments in liver cell spheroids suggest the drug may also restrain abnormally high expression of the ACE2 receptor - required for entry of the SARS-CoV-2 virus - in these cells, helping to reduce viral infection of the liver, and likely other organs and tissues that do not normally express high levels of the ACE2 receptor. Using AI-based analyses, Justin Stebbing and colleagues had previously identified baricitinib, approved for the treatment of rheumatoid arthritis, as a promising treatment for COVID-19. They also previously found that the drug can reduce levels of the pro-inflammatory cytokine IL-6 in rheumatoid arthritis patients. Noting that levels of IL-6 have been reported to correlate with symptom severity in patients with COVID-19, Stebbing et al. enrolled a total of 179 hospitalized patients from Pisa, Italy, and 422 from Albacete, Spain. In the Pisa cohort, 37 patients were given baricitinib once daily for two weeks; of the 142 controls, 37 were matched with the drug recipient group using a "propensity score" based on the patients' age, sex, and several parameters related to their medical history. In Albacete, 46 patients were given a lower dose of the drug for shorter periods of time, due to safety considerations in this elderly cohort. As in Pisa, 46 of the 376 control patients were matched with the drug recipient cohort using the propensity score method. Overall, across both cohorts matched by propensity score, the patients who received baricitinib either died or received invasive mechanical ventilation at roughly half the rate (16.9%) of the untreated group (34.9%). Stebbing et al. note that randomized trials of the drug are currently underway. Based on their own results - including their additional experiments in liver cell spheroids - the authors note that they "eagerly await" the results of these trials.

    ###
  2. Gradje 1960 15 november 2020 13:29
    [quote alias=Joseph K. id=12908717 date=202011151053]
    NEWS RELEASE 13-NOV-2020
    Approved JAK inhibitor baricitinib shows promise against cytokine storm in COVID-19 clinical study
    JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality

    AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE

    Research News

    SHARE PRINT E-MAIL
    A clinical study involving 601 patients in Italy and Spain suggests that the JAK inhibitor drug baricitinib may enhance survival rates of patients with severe COVID-19, primarily by blunting the runaway immune inflammation known as "cytokine storm." While the authors are careful to note that their study was not a fully randomized trial with a placebo control group, the drug nonetheless had a notable effect, particularly in the Spanish treatment cohort, composed entirely of elderly patients over the age of 70. This suggests the treatment could address high rates of COVID-19 morbidity and mortality observed in this demographic worldwide. Further in vitro experiments in liver cell spheroids suggest the drug may also restrain abnormally high expression of the ACE2 receptor - required for entry of the SARS-CoV-2 virus - in these cells, helping to reduce viral infection of the liver, and likely other organs and tissues that do not normally express high levels of the ACE2 receptor. Using AI-based analyses, Justin Stebbing and colleagues had previously identified baricitinib, approved for the treatment of rheumatoid arthritis, as a promising treatment for COVID-19. They also previously found that the drug can reduce levels of the pro-inflammatory cytokine IL-6 in rheumatoid arthritis patients. Noting that levels of IL-6 have been reported to correlate with symptom severity in patients with COVID-19, Stebbing et al. enrolled a total of 179 hospitalized patients from Pisa, Italy, and 422 from Albacete, Spain. In the Pisa cohort, 37 patients were given baricitinib once daily for two weeks; of the 142 controls, 37 were matched with the drug recipient group using a "propensity score" based on the patients' age, sex, and several parameters related to their medical history. In Albacete, 46 patients were given a lower dose of the drug for shorter periods of time, due to safety considerations in this elderly cohort. As in Pisa, 46 of the 376 control patients were matched with the drug recipient cohort using the propensity score method. Overall, across both cohorts matched by propensity score, the patients who received baricitinib either died or received invasive mechanical ventilation at roughly half the rate (16.9%) of the untreated group (34.9%). Stebbing et al. note that randomized trials of the drug are currently underway. Based on their own results - including their additional experiments in liver cell spheroids - the authors note that they "eagerly await" the results of these


    Heeft iemand met kennis van zaken enig idee of dit ook mogelijkheden voor filgotinib oplevert?

  3. MadisonAv 15 november 2020 15:06
    quote:

    Gradje 1960 schreef op 15 november 2020 13:29:




    Heeft iemand met kennis van zaken enig idee of dit ook mogelijkheden voor filgotinib oplevert?




    Veel te laat voor Filgotinib.

    Besides, Galapagos heeft wel wat anders te doen. Dat ze eerst maar de 1205 resultaten delen en in 2021 via Gilead Filgo in de US approved krijgen.
    Nu met Covid trials beginnen voor Filgo moet echt de laatste van hun zorgen zijn.
  4. forum rang 4 Down the drain 2 15 november 2020 20:43
    quote:

    Gradje 1960 schreef op 15 november 2020 13:29:


    [quote alias=Joseph K. id=12908717 date=202011151053]
    NEWS RELEASE 13-NOV-2020
    Approved JAK inhibitor baricitinib shows promise against cytokine storm in COVID-19 clinical study
    JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality

    AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE

    Research News

    SHARE PRINT E-MAIL
    A clinical study involving 601 patients in Italy and Spain suggests that the JAK inhibitor drug baricitinib may enhance survival rates of patients with severe COVID-19, primarily by blunting the runaway immune inflammation known as "cytokine storm." While the authors are careful to note that their study was not a fully randomized trial with a placebo control group, the drug nonetheless had a notable effect, particularly in the Spanish treatment cohort, composed entirely of elderly patients over the age of 70. This suggests the treatment could address high rates of COVID-19 morbidity and mortality observed in this demographic worldwide. Further in vitro experiments in liver cell spheroids suggest the drug may also restrain abnormally high expression of the ACE2 receptor - required for entry of the SARS-CoV-2 virus - in these cells, helping to reduce viral infection of the liver, and likely other organs and tissues that do not normally express high levels of the ACE2 receptor. Using AI-based analyses, Justin Stebbing and colleagues had previously identified baricitinib, approved for the treatment of rheumatoid arthritis, as a promising treatment for COVID-19. They also previously found that the drug can reduce levels of the pro-inflammatory cytokine IL-6 in rheumatoid arthritis patients. Noting that levels of IL-6 have been reported to correlate with symptom severity in patients with COVID-19, Stebbing et al. enrolled a total of 179 hospitalized patients from Pisa, Italy, and 422 from Albacete, Spain. In the Pisa cohort, 37 patients were given baricitinib once daily for two weeks; of the 142 controls, 37 were matched with the drug recipient group using a "propensity score" based on the patients' age, sex, and several parameters related to their medical history. In Albacete, 46 patients were given a lower dose of the drug for shorter periods of time, due to safety considerations in this elderly cohort. As in Pisa, 46 of the 376 control patients were matched with the drug recipient cohort using the propensity score method. Overall, across both cohorts matched by propensity score, the patients who received baricitinib either died or received invasive mechanical ventilation at roughly half the rate (16.9%) of the untreated group (34.9%). Stebbing et al. note that randomized trials of the drug are currently underway. Based on their own results - including their additional experiments in liver cell spheroids - the authors note that they "eagerly await" the results of these


    Heeft iemand met kennis van zaken enig idee of dit ook mogelijkheden voor filgotinib oplevert?



    Heb je wel eens uitgerekend wat het kost om een fase 3 trial te doen ? En daarna wat het oplevert om de Europese IC patienten mee te behandelen ? Die markt is gewoon te klein en (hopelijk) maar kort relevant.
  5. forum rang 6 Mippert 16 november 2020 00:17
    quote:

    slei schreef op 15 november 2020 22:37:


    op deze ruim € 100 gewoon vasthouden - wegleggen, tijdje niet naar kijken


    Jawel, je moet er juist WEL naar kijken. En elke euro UP vieren!
    Ik zie groene futs. Morgen (herstel: vandaag) pakken we vast de stijgende lijn weer op.

    Weekdoel: 115
  6. forum rang 10 voda 16 november 2020 07:09
    Beursblik: beleggers meer vertrouwen na overwinning Biden

    (ABM FN-Dow Jones) Nederlandse beleggers zijn in november positiever geworden over de toekomstige ontwikkelingen van de financiële markten. Dit blijkt dit weekend uit de Binck Beleggersbarometer.

    Dit gebeurde nadat bekend werd dat Joe Biden de presidentsverkiezingen in de VS heeft gewonnen.

    Beleggers verwachten volgens een enquête van Binck dat Europese beurzen het de komende maanden beter gaan doen en dat ook de euro zal gaan aantrekken ten opzichte van de dollar.

    De Binck Beleggersbarometer steeg van 0,2 in oktober naar een stand van 1,6 in november, op een schaal van -10 tot +10.

    De AEX zal volgens de enquête de komende maand met 1,6 procent stijgen en de S&P 500 index zelfs nog iets harder.

    De favoriete aandelen van klanten van Binck zijn Galapagos, ASML en Royal Dutch Shell. Opvallend is echter ook dat Shell bovenaan staat in de lijst van favoriete aandelen voor verkoop, samen met Air France-KLM en ING.

    De meest favoriete sector blijft Tech. Ook de medische sector blijft geliefd.

    Door: ABM Financial News.
    info@abmfn.nl
    Redactie: +31(0)20 26 28 999

    © Copyright ABM Financial News B.V. All rights reserved.
  7. forum rang 6 egeltjemetstekel 16 november 2020 09:08
    quote:

    Mippert schreef op 16 november 2020 08:50:


    Goedemorgen Galavriendjes. Wat zal deze dag ons weer gaan brengen?
    Ik verwacht een rustig verloop, met natuurlijk wel de dips van half tien en van de lunch. Uiteindelijk een slot van een euro hoger, dus weer terug naar 106,50 (op weg naar 115 eind van de week).
    meestal wat meer spektakel bij jou,
    Wel al koffie gehad?
  8. forum rang 6 Jestbread 16 november 2020 09:24
    quote:

    Sentiment schreef op 16 november 2020 07:45:


    Ik had begrepen dat er nog helemaal geen beslissing was en dat er nog rechtszaken liepen vanwege de fraude.....
    Inmiddels zijn er al 12 rechtszaken geannuleerd wegens een gebrek aan bewijs. Natuurlijk zijn deze verkiezingen voorbij. Het is alleen de vraag wanneer de Republikeinen dit toe gaan geven. Wat een waardeloze verliezers.
  9. forum rang 7 bezinteergebelegt 16 november 2020 09:55
    Trompet is passe, en gelukkig maar. Helaas is de koers van Gala voor de rest vh jaar ook passe. Had ik een week of wat terug, voor dat aangekondigde mega Toledo-event, nog de hoop dat dit jaar nog de 125/130 haalbaar zou zijn, maar inmiddels heb ik dat voor mezelf ook bijgesteld.

    Er zijn nog 5 serieuze beursweken dit jaar, daarna is het alweer gedaan met 2020 qua serieuze handel, en ik zie Gala niet meer boven de 110 komen de rest vh jaar.

    En dan vanaf 2021 maar hopen dat de koers wel serieus zal herstellen.
2.982 Posts
Pagina: «« 1 ... 95 96 97 98 99 ... 150 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Galapagos Meer »

Koers 44,120   Verschil -0,13 (-0,28%)
Laag 43,800   Volume 355.941
Hoog 44,325   Gem. Volume 359.852
21 okt 2021 17:38
Premium

Galapagos biedt beleggers nog geen houvast

Het laatste advies leest u als IEX Premium-lid

Inloggen Ontdek Premium

Gerelateerde Video's

  1. video thumbnail

    Galapagos gaat als de brandweer

    31 maart 2017 14:21 - Vimeo

  2. video thumbnail

    Arend Jan Kamp over hoofdkantoren

    7 februari 2017 16:38 - Vimeo

  3. video thumbnail

    Arend Jan Kamp over biotech

    2 februari 2017 16:33 - Vimeo

  4. video thumbnail

    Arend Jan Kamp over Galapagos

    9 juni 2016 16:08 - Vimeo

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links